From the USA: Pharmacogenomic Score Can Personalize Treatment of Leukemia in Children
For pediatric patients with acute myeloid leukemia (AML), a pharmacogenomics-based 10 single nucleotide polymorphism cytarabine (Ara-C) score (ACS10) can be used to tailor induction regimens, yielding improved outcomes, according to a study published online July 30 in Clinical Cancer Research.
Noting that low ACS10 has been shown to be associated with poor outcome in AML patients treated with standard chemotherapy, Richard J. Marrero, Pharm.D., from the University of Florida College of Pharmacy in Gainesville, and colleagues examined the ACS10 score in the context of three induction regimens. Low versus high ACS10 score groups were assessed for event-free (EFS) and overall survival (OS) among patients in two clinical trials (AML02 and AML08): AML02 low-dose cytarabine (LDAC; 91 patients), AML02+AML08 high-dose cytarabine (HDAC; 194 patients), and AML08 clofarabine+cytarabine (Clo/Ara-C; 105 patients).
Source: Advances and More licensed by HealthDay
